Juno: How Can CAR-T’s Big Loser Still Be Worth $2.5B? – Seeking Alpha
Seeking Alpha |
Juno: How Can CAR–T's Big Loser Still Be Worth $2.5B?
Seeking Alpha Novartis and Kite submitted applications to the FDA in March for Chimeric Antigen Receptor Engineered T cells targeting CD19 positive B cell leukemia and lymphoma, respectively. What would have been a Juno Therapeutics CD19 CAR-T candidate for … |
